Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-01-26 pm EST
168.89 USD   -0.37%
04:50pSector Update: Healthcare Stocks Climb Back to Finish Higher
MT
09:12aSector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
05:39aEvotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference

12/07/2022 | 04:31pm EST

Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.


ę Business Wire 2022
All news about JOHNSON & JOHNSON
04:50pSector Update: Healthcare Stocks Climb Back to Finish Higher
MT
09:12aSector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
05:39aEvotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
05:25aEvotec Shares Climb After Agreement With Janssen on Immunotherapies Development
DJ
04:07aEvotec Starts Oncology-development Collaboration With Johnson & Johnson Unit
MT
01/25Johnson & Johnson : JNJ-USQ_Transcript_FINAL 2023-01-24
PU
01/25Morgan Stanley Adjusts Price Target on Johnson & Johnson to $180 From $176, Maintains E..
MT
01/25Atlantic Equities Adjusts Johnson & Johnson's Price Target to $168 From $160, Keeps Neu..
MT
01/25MarketScreener's World Press Review, January 25
MS
01/25RLS Global Chairman to Depart in February; Successor Nominated
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 21,3x
Yield 2022 2,61%
Capitalization 442 B 442 B -
EV / Sales 2022 4,53x
EV / Sales 2023 4,30x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 168,89 $
Average target price 181,45 $
Spread / Average Target 7,44%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.72%443 181
ELI LILLY AND COMPANY-5.32%332 306
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-2.13%275 319
ABBVIE INC.-8.55%261 275